
    
      To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197 given
      orally. This is an open label, dose escalation study of ARQ 197 administered orally at a
      starting dose of 10 mg bid (20 mg/day).
    
  